Curcumin, a naturally occurring phytochemical and principal component of Curcuma longa, has exhibited broad pharmacological properties including antioxidant, anti-inflammatory, anti-cancer and anti-viral effects (Khor et al., 2019; Kocaadam & Şanlier, 2017; Lal et al., 2016; Wiggers et al., 2017). Curcumin and its derivatives, due to its rich conventional medicinal interest, has undergone comprehensive in vitro and in vivo studies. It has, therefore, been associated with more than 100 cellular targets, including cytokines, proteins, transcription factors, and receptors. Previous studies have shown the potential of curcumin as a treatment against Influenza A virus infection, by an effect mediated by modulating immune response to prevent injury to the lung tissue (Han et al., 2018). Curcumin has also been shown to have anti neuraminidase (NA) activity for the influenza virus NA protein (Richart et al., 2018). Therefore, in the present study, curcumin and its derivatives were docked onto the spike protein of the SARS-CoV and the SARS-CoV-2 to predict the binding interactions.